NEW YORK, July 26, 2026, 4:00 p.m. EDT — Viking Therapeutics (NASDAQ:VKTX) is under the microscope as it prepares to report second-quarter results after the market closes on Wednesday, July 29. The stock closed at $34.79 on Friday, down 6.2% for the week, with a 1.7% decline on the final trading day alone.
The primary concern for investors is the company's cash position. Viking's operating cash burn has more than doubled year-over-year to $114.0 million in the first quarter, while research spending surged 263% to $150.2 million. A straight-line estimate suggests that March's liquidity of $603 million covers only 5.3 quarters of first-quarter cash burn, though the company has stated its cash should last until at least June 30, 2027.
Earnings Estimates Worsen
Analysts have significantly revised their expectations downward over the past three months. The average estimate for the second-quarter loss has increased by 24% to $1.23 per share. The projected full-year 2026 loss has grown by 18% to $4.75 per share. These changes reflect rising expenditures as the company advances its clinical pipeline.
The market capitalization stood at $4.02 billion on Friday, with a liquidity surplus of approximately $3.42 billion over March's cash holdings, not accounting for other assets and liabilities.
Key Catalysts Ahead
Viking is approaching several important milestones. Data on maintenance dosing for its lead obesity candidate, VK2735, is expected this quarter, with an oral Phase 3 trial scheduled to begin in the fourth quarter. The company is also strengthening its commercial capabilities, with CEO Brian Lian stating last week that Viking is “preparing for VK2735’s potential launch” while announcing the addition of a new director.
Competitive Landscape Heats Up
The competitive environment has intensified. Eli Lilly (NYSE:LLY) reported a 22.6% weight loss in a Phase 3 trial for retatrutide, with a separate diabetes study showing a 20.8% reduction. Lilly plans to submit a U.S. application in the first quarter of 2027, with Executive Vice President Kenneth Custer calling retatrutide “an important future tool” for cardiometabolic conditions.
On Friday, the market reflected this divergence. Lilly shares rose 0.9%, Novo Nordisk (NYSE:NVO) gained 1.3%, while Viking fell 1.7%.
Analyst Views Remain Binary
Price targets for Viking span a wide range. The lowest estimate is $34, nearly matching Friday’s closing price, while the consensus average stands at $94.29. This highlights the binary outlook for the stock as it trades without revenue and faces significant clinical and regulatory risks.
Wednesday’s earnings call is expected to address three key areas: cash levels, research expenditure, and any modifications to runway projections. The schedule for third-quarter data will also come under scrutiny.
Risks remain elevated. Viking generates no revenue, and advanced trials could face delays or failure. Accelerated spending may lead to earlier dilution, while Lilly’s strong data could set a higher efficacy bar. For now, the balance sheet may drive share movement ahead of trial results.
